Literature DB >> 11908571

Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines.

Wendy He1, Jean-Pierre Pelletier, Johanne Martel-Pelletier, Stefan Laufer, John A Di Battista.   

Abstract

OBJECTIVE: To determine the level of leukotriene B4 (LTB4) synthesized and released by synovium of patients with osteoarthritis (OA), and to study the role of lipoxygenase (LO)/cyclooxygenase (COX) products on proinflammatory cytokine and interstitial collagenase (MMP-1) synthesis.
METHODS: Human OA synovial explants were cultured in the presence of lipopolysaccharide (L) and the ionophores ionomycin (I) and thapsigargin (T) (LIT) for 72 h at 37 degrees C, and LTB4 released into the culture medium was measured in the absence or presence of a COX-2-specific inhibitor, NS-398, or the 5-LO activating protein inhibitor Bay-x-1005. Increasing concentrations of LTB4 (10(-9) to 10(-6) M) were incubated with explants for 24 h at 37 degrees C, and interleukin 1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in the conditioned medium were quantitated by ELISA. The effect of endogenous eicosanoids on basal and induced levels of IL-1beta, TNF-alpha, and MMP-1 synthesis was examined by incubating explants in the presence of NS-398 and Bay-x-1005. The effect of antiinflammatory cytokines rhIL-4, IL-10, and IL-13 on basal and LTB4 dependent stimulation of IL-1beta/TNF-alpha synthesis was studied under titration conditions.
RESULTS: Physiologically relevant concentrations (10(-10) to 10(-9) mol/l) of LTB4 were produced in the presence of LIT. Bay-x-1005 abrogated LTB4 release, while NS-398 was without effect. LTB4 stimulated IL-1beta and TNF-alpha synthesis with an EC50 of 190 +/- 35 and 45 +/- 9 nmol/l, respectively. Significant concentrations of IL-1beta and TNF-alpha were released (100-200 and 500-600 pg/ml, respectively). Basal and LIT induced IL-1beta and TNF-alpha production were inhibited by Bay-x-1005 in a dose dependent manner, while the addition of NS-398 caused a potent stimulatory effect. The preferential COX-2 inhibitor also induced MMP-1 synthesis in a manner essentially identical to the proinflammatory cytokines. The antiinflammatory cytokine IL-4 blocked LTB4 dependent stimulation of IL-1beta and TNF-alpha synthesis. In contrast, IL-10 markedly stimulated both cytokines when incubated alone or in the presence of LTB4 where the effect was additive.
CONCLUSION: Endogenous and locally produced eicosanoids regulate proinflammatory cytokine and MMP-1 synthesis under basal and stimulated conditions in vitro, with leukotrienes and prostaglandins having opposite effects in general. The clinical use of antiinflammatory drugs that inhibit eicosanoid synthesis requires an appreciation of their relative capacity to inhibit LO/COX in order to predict their effect on the synthesis of proinflammatory cytokines and matrix metalloproteases. IL-10 stimulated proinflammatory cytokine synthesis in our ex vivo culture system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11908571

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  23 in total

1.  Leukotriene B(4) BLT receptor signaling regulates the level and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of Ras/Raf/ERK/p42 AUF1 pathway.

Authors:  Beibei Zhai; Huiqing Yang; Arturo Mancini; QingWen He; John Antoniou; John A Di Battista
Journal:  J Biol Chem       Date:  2010-05-19       Impact factor: 5.157

Review 2.  The cardinal role of the phospholipase A(2)/cyclooxygenase-2/prostaglandin E synthase/prostaglandin E(2) (PCPP) axis in inflammostasis.

Authors:  A D Mancini; J A Di Battista
Journal:  Inflamm Res       Date:  2011-10-01       Impact factor: 4.575

Review 3.  Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis.

Authors:  William H Robinson; Christin M Lepus; Qian Wang; Harini Raghu; Rong Mao; Tamsin M Lindstrom; Jeremy Sokolove
Journal:  Nat Rev Rheumatol       Date:  2016-08-19       Impact factor: 20.543

Review 4.  The analgesic potential of glycosides derived from medicinal plants.

Authors:  Haroon Khan; Aini Pervaiz; Sebastiano Intagliata; Niranjan Das; Kalyan C Nagulapalli Venkata; Atanas G Atanasov; Agnieszka Najda; Seyed Mohammad Nabavi; Dongdong Wang; Valeria Pittalà; Anupam Bishayee
Journal:  Daru       Date:  2020-02-14       Impact factor: 3.117

Review 5.  Licofelone: the answer to unmet needs in osteoarthritis therapy?

Authors:  Shrinivas K Kulkarni; Vijay P Singh
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

Review 6.  Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.

Authors:  J Martel-Pelletier; D Lajeunesse; P Reboul; J-P Pelletier
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

Review 7.  Persisting eicosanoid pathways in rheumatic diseases.

Authors:  Marina Korotkova; Per-Johan Jakobsson
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

8.  Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac.

Authors:  M A Alvarez-Soria; R Largo; J Santillana; O Sánchez-Pernaute; E Calvo; M Hernández; J Egido; G Herrero-Beaumont
Journal:  Ann Rheum Dis       Date:  2006-02-13       Impact factor: 19.103

9.  An exploration of the ability of tepoxalin to ameliorate the degradation of articular cartilage in a canine in vitro model.

Authors:  Lisa Macrory; Anne Vaughan-Thomas; Peter D Clegg; John F Innes
Journal:  BMC Vet Res       Date:  2009-07-22       Impact factor: 2.741

Review 10.  Activity and potential role of licofelone in the management of osteoarthritis.

Authors:  Arrigo F G Cicero; Luca Laghi
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.